It was in early 2014 that my veterinarian friend first recommended I look into CBD oil for dogs. My oldest dog was suffering from arthritis and my middle dog had recently begun suffering from severe anxiety any time I walked toward the door. The CBD oil did wonders for both my dogs. Since then, I’ve been a strong advocate for CBD Treats and Oil for Dogs.
For anxiety, CBD products with a ratio of 20:1 or higher are recommended and administered as drops, capsules, or edibles. High-CBD cannabinoids can be very effective in reducing chronic anxiety, treating temporary stress, and protecting the body from the physiological effects of both. Varieties high in linalool, a terpene shared with lavender, are known to be effective for relieving anxiety. In particular the strain AC/DC is very effective.
Cost is another consideration. Most CBD oils are sold in concentrations of 300 to 750 mg, although this may range from less than 100 mg to more than 2,000. A good indicator of price-point is the cost per milligram. Low-cost CBD oils usually fall between five and 10 cents per mg; mid-range prices are 11 to 15 cents per mg; and higher-end oils cost 16 cents per mg or higher. Given these varying per-milligram costs, a bottle of CBD oil may be priced anywhere from $10 or less to $150 or more.
I decided to try CBD when I was withdrawing from Tramadol, a synthetic opiate I had been taking for pain (with 2 other medications) for over a year. As I began slowly reducing my use, I experienced a lot of anxiety and muscle tremors in my legs especially. I know that using a marijuana medication meant that my pain doctor would not prescribe for me again, but I was getting off the pain medications one by one anyway, so I don't care.
There are new CBD companies coming online every week – these span the range from truly awful to really great. So how to choose the best? The quality of the CBD oil itself is obviously the most important factor – and many companies do take the quality of their products seriously. To reward those companies, we gave more weight to the quality of the product than any other category.
Following cloning of the endogenous receptor for THC, namely the CB1R, endogenous CB1R ligands, or “endocannabinoids” (eCBs) were discovered, namely anandamide (AEA) and 2-arachidonoylglycerol (reviewed in ). The CB1R is an inhibitory Gi/o protein-coupled receptor that is mainly localized to nerve terminals, and is expressed on both γ-aminobutryic acid-ergic and glutamatergic neurons. eCBs are fatty acid derivatives that are synthesized on demand in response to neuronal depolarization and Ca2+ influx, via cleavage of membrane phospholipids. The primary mechanism by which eCBs regulate synaptic function is retrograde signaling, wherein eCBs produced by depolarization of the postsynaptic neuron activate presynaptic CB1Rs, leading to inhibition of neurotransmitter release . The “eCB system” includes AEA and 2-arachidonoylglycerol; their respective degradative enzymes fatty acid amide hydroxylase (FAAH) and monoacylglycerol lipase; the CB1R and related CB2 receptor (the latter expressed mainly in the periphery); as well as several other receptors activated by eCBs, including the TRPV1 receptor, peroxisome proliferator-activated receptor-γ, and G protein-coupled 55 receptor, which functionally interact with CB1R signaling (reviewed in [21, 24]). Interactions with the TRPV1 receptor, in particular, appear to be critical in regulating the extent to which eCB release leads to inhibition or facilitation of presynaptic neurotransmitter release . The TRPV1 receptor is a postsynaptic cation channel that underlies sensation of noxious heat in the periphery, with capsacin (hot chili) as an exogenous ligand. TRPV1 receptors are also expressed in the brain, including the amygdala, periaqueductal grey, hippocampus, and other areas [26, 27].
In the United States, non-FDA approved CBD products are classified as Schedule I drugs under the Controlled Substances Act. This means that production, distribution, and possession of non-FDA approved CBD products is illegal under federal law. In addition, in 2016 the Drug Enforcement Administration added "marijuana extracts" to the list of Schedule I drugs, which it defined as "an extract containing one or more cannabinoids that has been derived from any plant of the genus Cannabis, other than the separated resin (whether crude or purified) obtained from the plant." Previously, CBD had simply been considered "marijuana", which is a Schedule I drug.